Prophylactic sodium thiosulfate reduces the risk and severity of acute kidney injury in oxaliplatin-based hyperthermic intraperitoneal chemotherapy

Table 5 Adjusted risk analysis of postoperative complications (except acute kidney injury) estimated by logistic regression

Variable	No complications (n = 59)	Complications (n = 60)	Univariate analysis		Multivariate analysis
			P value	OR (95%CI)	P value	OR (95%CI)
Sodium thiosulfate
No	28	45	Reference	-	-	-
Yes	31	15	0.002	0.30 (0.14-0.65)	0.29	0.56 (0.19-1.64)
Age
≤ 59	26	26	Reference	-	0.91	0.95 (0.39-2.30)
> 59	33	34	0.94	1.03 (0.50-2.13)	-	-
Sex
Male	26	33	Reference	-	-	-
Female	33	27	0.23	0.66 (0.31-1.33)
Cardiovascular comorbidities1
0	27	22	Reference	-	-	-
1	15	22	0.18	1.80 (0.76-4.27)	0.38	1.56 (0.57-4.26)
≥ 2	17	16	0.75	1.16 (0.48-2.80)	0.52	1.42 (0.49-4.16)
ASA classification
1	26	22	Reference	-	-	-
2	24	27	0.48	1.33 (0.60-2.93)
3	9	11	0.49	1.44 (0.51-4.12)
Reduced IP dose
No	42	40	Reference	-	-	-
Yes	17	20	0.6	1.24 (0.57-2.69)	0.6	0.77 (0.29-2.06)
Neoadjuvant chemotherapy
No	49	43	Reference	-	-	-
Yes	10	17	0.14	1.94 (0.80-4.68)
Chemotherapy naive
No	35	34	Reference	-	-	-
Yes	24	26	0.77	1.12 (0.54-2.31)
Operating time
≤ 537 minutes	41	19	Reference	-	-	-
> 537 minutes	18	41	< 0.001	4.92 (2.26-10.7)	0.005	4.09 (1.54-10.8)
Bleeding
≤ 600 mL	33	32	Reference	-	-	-
> 600 mL	26	28	0.78	1.11 (0.54-2.29)	0.82	0.90 (0.37-2.22)
Intraoperative hypotension (minute)
None	32	30	Reference	1.60 (0.51-5.04)	0.83	1.16 (0.31-4.36)
0-7.12	6	9	0.42	1.01 (0.46-2.24)	0.96	0.97 (0.38-2.45)
> 7.12	21	20	0.97	-	-	-
Peak lactic acid level
< 2.4	37	25	Reference	2.36 (1.13-4.92)	0.49	1.38 (0.55-3.43)
≥ 2.4	22	35	0.02
Postoperative inotropy
≤ 32 hours	36	36	Reference	-	-	-
> 32 hours	22	21	0.98	0.96 (0.45-2.03)	0.76	0.87 (0.36-2.10)

¹Diabetes mellitus, hypertension, smoking, body mass index ≥ 30, history of myocardial infarction or peripheral arterial insufficiency.

CI: Confidence interval; OR: Odds ratio; ASA: American Society of Anesthesiologists; IP: Intraperitoneal chemotherapy.